Navigation Links
GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Date:9/12/2007

ATLANTA, Sept. 12 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced the presentation of successful human trial results for its HIV/AIDS vaccines at the AIDS Vaccine 2007 Conference held August 20-23, 2007 in Seattle, Washington.

GeoVax HIV/AIDS human trial results were presented by Dr. Paul Goepfert, MD in a talk "HIV-1 DNA Prime followed by Recombinant MVA Boost is Well Tolerated and Immunogenic When Administered to Healthy Seronegative Adults." Dr. Goepfert, from the University of Alabama-Birmingham, is Protocol Chair of HVTN 065, a series of human clinical trials currently evaluating GeoVax's HIV/AIDS vaccine.

GeoVax HIV/AIDS vaccine trial data was presented to over 900 AIDS researchers at the week long conference. Conference Chair, Dr. Lawrence Corey stated, "It has become clear that a preventative vaccine is essential to controlling the global AIDS epidemic." The AIDS Vaccine 2007 Conference was organized under the guidance of the Global HIV Vaccine Enterprise, an alliance of independent global organizations dedicated to accelerating preventative AIDS vaccine development.

The conference reported the AIDS epidemic continuing as a global threat with the disease increasing in every region of the world, especially East and Central Asia and Eastern Europe where AIDS incidence was 21% higher in 2006 than in 2004.

Key GeoVax HIV/AIDS Vaccine Human Trial conclusions presented at the AIDS Vaccine 2007 Conference included:

-- GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-

HIV/AIDS immune responses) at both low (1/10th) dose and full doses.

-- GeoVax vaccines were well tolerated with no or mild local and systemic

reactions in the majority of trial participants.

-- 80% of both the low and full dose trial participants responded to the

vaccine which stimulated highly desirable anti-HIV T-cell (white blood'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the ... Healthcare Distribution Specialist, LLC ("HDS") are pleased to announce ... Vitamin & Sports Nutrition Expo to be held at ... Florida on July 15-17, 2012.  As part of the ...
... announced today the Clinical Laboratory Responsibility Pledge, a ... ethical business practices in the medication monitoring industry. ... adheres and to which the company challenges every ... adopt. (Logo: http://photos.prnewswire.com/prnh/20120203/LA47138LOGO ) ...
Cached Medicine Technology:Sunpeaks Ventures to Participate in ECRM Conference and Expo 2Sunpeaks Ventures to Participate in ECRM Conference and Expo 3Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3
(Date:4/18/2014)... A group of scientists from the University of ... on Aging has found interesting new information in ... Parkinson,s disease (PD). , Published in the ... assessed cognitive function in depressed and non-depressed patients ... commonly used to treat motor symptoms of Parkinson,s ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Expected to Achieve Strong Uptake in this ... from Decision ResourcesWALTHAM, Mass., April 30 ... research and advisory firms for pharmaceutical and ... Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s Remicade, and Abbott/Eisai,s ...
... creates federal-state-local partnership to help fight domestic violence, ... $1.1 million U.S. Justice Dept. grant is fueling ... to help combat domestic violence and sexual assault ... Appellate Prosecutor,s office has hired two full-time prosecutors ...
... steroid to multiple sclerosis treatment shows promise in study ... steroid drug in combination with a multiple sclerosis (MS) ... using the MS drug alone, suggests a new study. ... relapsing-remitting MS, some patients were randomly selected to receive ...
... of the pancreas, invagination of the pancreas into the ... fistula, according to researchers at the Jefferson Pancreas, Biliary ... the Journal of the American College of Surgeons ... the gold standard for studies. , Removing the head ...
... 2008...sales up 266%, , ... Winston-Salem, ... today that it is expanding its corporate and satellite offices ... stabilization system, VerteLoc™. , , , , ,"We are essentially ...
... principles for Getting Health IT Right under the American ... the Markle Foundation hosts a forum to discuss the ... (IT) under the American Recovery and Reinvestment Act (ARRA). ... with government and policy experts to talk about how ...
Cached Medicine News:Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 3
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
The CRW system epitomizes simplicity, quality assurance, and versatility....
Used to negotiate tortuous vessels....
Hydrosteer wires are intended for use in the percutaneous introduction of catheters....
Medicine Products: